FLXN Insider Trading Activity and SEC Form 4 Filings
FLXN insider trading summary
No open-market insider purchases or sales of Flexion Therapeutics Inc (FLXN) have been reported on SEC Form 4 in the past 12 months.
Latest FLXN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 19, 2021 | Adam Muzikant | Chief Business Officer | Sell | $12K (1,870 @ $6.45) |
| Jul 19, 2021 | Mark S. Levine | General Counsel | Sell | $25K (3,945 @ $6.45) |
| Jul 19, 2021 | Kerry Wentworth | Chief Regulatory Officer | Sell | $25K (3,944 @ $6.45) |
| Jul 19, 2021 | Christina Willwerth | Chief Strategy Officer | Sell | $25K (3,945 @ $6.45) |
| May 10, 2021 | David Arkowitz | Chief Financial Officer | Sell | $16K (2,229 @ $7.23) |
| Mar 15, 2021 | Melissa Layman | Chief Commercial Officer | Sell | $53K (4,520 @ $11.80) |
| Jan 28, 2021 | Melissa Layman | Chief Commercial Officer | Sell | $33K (2,624 @ $12.55) |
| Jan 5, 2021 | David Arkowitz | Chief Financial Officer | Sell | $68K (6,073 @ $11.13) |
| Jan 5, 2021 | Scott Kelley | Chief Medical Officer | Sell | $76K (6,829 @ $11.13) |
| Jan 5, 2021 | Christina Willwerth | Chief Strategy Officer | Sell | $73K (6,602 @ $11.13) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.